

University of Groningen

## Cardiac catheterization in children with pulmonary hypertensive vascular disease

PVRI Pediatric Task Force members; del Cerro, Maria Jesus; Moledina, Shahin; Haworth, Sheila G.; Ivy, Dunbar; Al Dabbagh, Maha; Banjar, Hanaa; Diaz, Gabriel; Heath-Freudenthal, Alexandria; Galal, Ahmed Nasser

*Published in:*  
Pulmonary circulation

*DOI:*  
[10.1086/685102](https://doi.org/10.1086/685102)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

PVRI Pediatric Task Force members, del Cerro, M. J., Moledina, S., Haworth, S. G., Ivy, D., Al Dabbagh, M., Banjar, H., Diaz, G., Heath-Freudenthal, A., Galal, A. N., Humpl, T., Kulkarni, S., Lopes, A., Mocumbi, A. O., Puri, G. D., Rossouw, B., Harikrishnan, S., Saxena, A., Udo, P., ... Adatia, I. (2016). Cardiac catheterization in children with pulmonary hypertensive vascular disease: Consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. *Pulmonary circulation*, 6(1), 118-125. <https://doi.org/10.1086/685102>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces

Maria Jesus del Cerro,<sup>1</sup> Shahin Moledina,<sup>2</sup> Sheila G. Haworth,<sup>3</sup> Dunbar Ivy,<sup>4</sup> Maha Al Dabbagh,<sup>5</sup> Hanaa Banjar,<sup>6</sup> Gabriel Diaz,<sup>7</sup> Alexandria Heath-Freudenthal,<sup>8</sup> Ahmed Nasser Galal,<sup>5</sup> Tilman Humpl,<sup>9</sup> Snehal Kulkarni,<sup>10</sup> Antonio Lopes,<sup>11</sup> Ana Olga Mocumbi,<sup>12</sup> G. D. Puri,<sup>13</sup> Beyra Rossouw,<sup>14</sup> S. Harikrishnan,<sup>15</sup> Anita Saxena,<sup>16</sup> Patience Udo,<sup>17</sup> Lina Caicedo,<sup>18</sup> Omar Tamimi,<sup>19</sup> Ian Adatia<sup>20,a</sup>

<sup>1</sup>Ramón y Cajal University Hospital, Madrid, Spain; <sup>2</sup>Great Ormond Street Hospital, London, United Kingdom; <sup>3</sup>University College London, London, United Kingdom; <sup>4</sup>Children's Hospital Colorado, Aurora, Colorado, USA; <sup>5</sup>King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia; <sup>6</sup>King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; <sup>7</sup>Universidad Nacional de Colombia, Bogota, Colombia; <sup>8</sup>Kardiozentrum, La Paz, Bolivia; <sup>9</sup>University of Toronto and Hospital for Sick Children, Toronto, Ontario, Canada; <sup>10</sup>Kokilaben Dhirubai Ambani Hospital and Medical Research Institute, Mumbai, India; <sup>11</sup>University of São Paulo, São Paulo, Brazil; <sup>12</sup>National Institute of Health, Maputo, Mozambique; <sup>13</sup>Postgraduate Institute of Medical Education and Research, Chandigarh, India; <sup>14</sup>University of Cape Town, Cape Town, South Africa; <sup>15</sup>Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India; <sup>16</sup>All-India Institute of Medical Sciences, New Delhi, India; <sup>17</sup>University of Uyo Hospital, Uyo, Nigeria; <sup>18</sup>Clinica Shaio, Bogota, Colombia; <sup>19</sup>King Saud bin Abdulaziz University, Riyadh, Saudi Arabia; <sup>20</sup>Stollery Children's Hospital, Edmonton, Alberta, Canada; <sup>a</sup>on behalf of the PVRI Pediatric Task Force members Steven Abman, Vera Aiello, Rolf Berger, Patricia Cortez, Jeffrey Fineman, Marilyné Lévy, Marlene Rabinovitch, J. Usha Raj, Irwin Reiss, Julio Sandoval, Kurt Stenmark, and Rao Sureshi.

**Abstract:** Cardiac catheterization is important in the diagnosis and risk stratification of pulmonary hypertensive vascular disease (PHVD) in children. Acute vasoreactivity testing provides key information about management, prognosis, therapeutic strategies, and efficacy. Data obtained at cardiac catheterization continue to play an important role in determining the surgical options for children with congenital heart disease and clinical evidence of increased pulmonary vascular resistance. The Pediatric and Congenital Heart Disease Task Forces of the Pulmonary Vascular Research Institute met to develop a consensus statement regarding indications for, conduct of, acute vasoreactivity testing with, and pitfalls and risks of cardiac catheterization in children with PHVD. This document contains the essentials of those discussions to provide a rationale for the hemodynamic assessment by cardiac catheterization of children with PHVD.

Pulm Circ 2016;6(1):118-125. DOI: 10.1086/685102.

Cardiac catheterization is important in the diagnosis and risk stratification of pulmonary hypertensive vascular disease (PHVD) in children. Acute vasoreactivity testing provides key information about management, prognosis, therapeutic strategies, and efficacy. Data obtained at cardiac catheterization continue to play an important role in determining the surgical options for children with congenital heart disease and clinical evidence of increased pulmonary vascular resistance. Hemodynamics (pressures, systemic and pulmonary blood flow, and vascular resistance index) obtained at cardiac catheterization relate directly to outcome.<sup>1</sup> Cardiac catheterization can be applied uniformly across all age groups and neurodevelopmental stages to demonstrate disease progression or regression and response to therapy.<sup>2</sup> Current guidelines for evaluation of pulmonary hypertension in adults<sup>3</sup> include recommendations for cardiac catheterization, with specific definitions, and discussion of prognostic

and therapeutic implications of a positive acute vasoreactivity test. The functional classification, diagnostic spectrum, phenotype, and progression of PHVD in children differ from those in adults and have been discussed by Pulmonary Vascular Research Institute (PVRI) task forces.<sup>2,4,5</sup> These differences directly affect the conduct of, data required for, and value of cardiac catheterization undertaken in children with disorders of the pulmonary circulation.

The aim of this document is to provide a comprehensive, globally applicable guideline for cardiac catheterization in pediatric PHVD. It reflects the ideas and experience of the Pediatric Task Forces at the sixth and seventh PVRI meetings held in Cape Town, South Africa (February 2012) and Istanbul, Turkey (January 2013). Members of the Pediatric Task Forces included pediatric specialists from cardiology, pulmonology, anesthesiology, cardiac critical care, cardiac surgery, and neonatology, with global representation from 12 countries.

Address correspondence to Dr. Ian Adatia, 3A2.43, Stollery Children's Hospital, 8440 112 Street NW, Edmonton, Alberta T6G 3B7, Canada. E-mail: iadatia@ualberta.ca.

Submitted October 15, 2015; Accepted November 28, 2015; Electronically published January 22, 2016.  
© 2016 by the Pulmonary Vascular Research Institute. All rights reserved. 2045-8932/2016/0601-0014. \$15.00.

## DIAGNOSTIC EVALUATION BEFORE CARDIAC CATHETERIZATION

Invasive hemodynamic evaluation should, in general, be the last diagnostic procedure, and all the results of the previous tests should be integrated and reviewed when deciding the best approach to cardiac catheterization for every patient. The diagnostic algorithm for pediatric PHVD differs from that used in adult patients, and specific tests (e.g., for congenital metabolic diseases, gastroesophageal reflux disease) may be needed in the evaluation of children. At the PVRI Pediatric Task Force meeting there was general agreement that a contrast-enhanced computed tomography (CT) scan (preferably high-resolution) be undertaken whenever possible before cardiac catheterization, as it will permit a focused approach to cardiac catheterization, shorten fluoroscopy time, and limit the radiopaque contrast required. CT scanning is extremely helpful to evaluate suspected pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, or interstitial lung disease, the exclusion or evaluation of congenital lung or heart malformations (e.g., anomalous systemic or pulmonary drainage, pulmonary sequestration, aortopulmonary collaterals, lung hypoplasia, pulmonary vein stenosis, airway malformations), and the extent of parenchymal lung disease in bronchopulmonary dysplasia (BPD). The new 320 multislice CT scanners minimize the radiation dose and the acquisition time, making sedation unnecessary. Magnetic resonance imaging (MRI) is a useful tool not only to study anatomy in congenital heart disease but also to evaluate right ventricular size and function, and it may have a role in the measurement of cardiac output, quantification of flow to each lung, or flow derived from collaterals.<sup>6</sup> Newer real-time imaging sequences may make it feasible in even young children without the need for sedation or general anesthetic.<sup>7</sup> However, it is not considered a replacement for cardiac catheterization but an extremely useful adjunct, especially in follow-up evaluations of response to treatment.<sup>8</sup> Needless to say, MRI with specialized evaluations for PHVD remains limited by the expense of the equipment and the scarcity of qualified persons to perform the scans and to interpret the findings.

## INDICATIONS FOR CARDIAC CATHETERIZATION IN PEDIATRIC PHVD

In general, the diagnosis of PHVD will have been made or suggested on the basis of a review of the clinical and family history, electrocardiography, chest x-ray, and echocardiographic assessment. Physicians who treat children with PHVD agree that cardiac catheterization is required to confirm the diagnosis and evaluate severity and prognosis.<sup>1,9</sup> It may be a useful adjunct to guide and assess the effects of therapy that can be applied across all ages and neurodevelopmental stages.<sup>2</sup> In addition, in PHVD associated with unrepaired congenital heart disease, hemodynamic evaluation by cardiac catheterization plays a key role in the assessment of suitability for shunt closure, especially in patients who present late or without clinical signs of excessive pulmonary blood flow despite an anatomically large defect or signs of right-to-left shunting.<sup>10</sup>

There is a broad consensus that a diagnostic cardiac catheterization with acute vasoreactivity testing be undertaken at least once in any patient with important pulmonary hypertension, especially

if targeted pulmonary hypertensive therapy is indicated. Exceptions to this rule include transient forms of PHVD (e.g., persistent pulmonary hypertension of the newborn), patients receiving inhaled nitric oxide (NO) therapy in the intensive care unit, and those in severe right heart failure. In very sick children or babies (Panama functional class IV, significant right ventricular dysfunction, extremely low weight, or hemodynamic instability), it may be prudent to start therapy and postpone the catheterization until the patient's clinical condition improves.<sup>11</sup> Risks and benefits of catheterization should be assessed in each case, and it may be appropriate in some children to treat without catheterization. In addition, catheterization may be forgone in patients with established Eisenmenger syndrome, with appropriate clinical and noninvasive diagnostic evaluations.

In general, we recommend repeating cardiac catheterization 6–12 months after the initiation of targeted PHVD therapy, before a change in therapy, and if there is any change in clinical status that requires further clarification. However, each individual case deserves careful scrutiny, as well as consideration of the institutional experience, to deal with complications and adverse events. Parental attitude, the assent of the child or adolescent, and the financial burden of repeat cardiac catheterization should be taken into account in different settings and countries.

## GENERAL ANESTHESIA VERSUS SEDATION

Optimally, catheterization to obtain basal measurements of pulmonary pressures, resistances, and cardiac output would be performed in an awake, but relaxed, cooperative child, using only local anesthesia. Unfortunately, this is not possible in the majority of patients under 12 years of age, and in older patients the neurodevelopmental maturity of the child will determine the degree of cooperation. Therefore, most catheterizations are performed either under general anesthesia with endotracheal intubation (or laryngeal mask airway) and mechanical ventilation or with sedation, allowing the patient to breathe spontaneously. For patients being submitted for their first diagnostic catheterization, the decision to withdraw pulmonary hypertension-specific therapy before the catheterization in order to obtain “basal measurements” should be taken on a case-by-case basis. In patients undergoing follow-up cardiac catheterization to assess the effects of therapy or the need for additional therapy, we recommend that specific drug therapy should be continued according to the outpatient schedule, even during the period of fasting before the procedure.<sup>11</sup>

We recommend the presence of an anesthesiologist familiar with the management of neonatal and childhood PHVD when either sedation or general anesthesia is used. Spontaneous breathing with sedation has the potential risk of respiratory depression and hypercapnia, which may alter pulmonary artery pressures and resistances. End-tidal CO<sub>2</sub> or partial pressure of CO<sub>2</sub> in arterial blood by blood gas analysis should be monitored closely, and an attempt should be made to mirror the normal cardiopulmonary state of the patient. This is particularly important in children with BPD who may have chronic CO<sub>2</sub> retention.

General anesthesia and mechanical ventilation provide stable conditions and adequate analgesia and avoid hypercarbia and hypoxia but require the availability of a trained pediatric anesthesiolo-

gist with experience in the management of children with cardiopulmonary disease. Nevertheless, it also has its disadvantages: general anesthesia may modify myocardial performance and lower systemic arterial pressure and vascular resistances. The serious-complication rates of cardiac catheterization in children with pulmonary hypertension range from 2% to 6%, and mortality ranges from 0% to 1.4%.<sup>9,11-18</sup> Complications are related to hypoxemia, hypercapnia, acidemia, hypothermia, tachycardia, or systemic hypotension. Children under 2 years of age may have a 3-fold increased risk of the complications from cardiac catheterization.<sup>17</sup>

The risks of general anesthesia, sedation, and cardiac catheterization are predictably increased in certain groups. A profile of a patient who requires careful evaluation by the team would include new diagnosis of PHVD, treatment naivete, advanced functional class (III/IV), right ventricular dysfunction, suprasystemic pulmonary artery (PA) pressure, age younger than 3 years, left ventricular systolic dysfunction, or restrictive cardiomyopathy.<sup>11</sup>

We recommend highly that there be discussion between the pediatric anesthesiologist, the pediatric pulmonary hypertension expert, and the cardiac catheterization team before cardiac catheterization to carefully evaluate the best approach to obtain the required data. Specific recommendations for anesthetizing patients with pulmonary hypertension have been published but will have to be modified, depending on the child, the local experience, and the resources available.<sup>19</sup> Clearly vulnerable moments for the patient are induction and emergence from anesthesia and procedural events associated with systemic hypotension that render the right ventricle performing at suprasystemic pressures especially prone to ischemia.<sup>20</sup> Careful postcatheterization monitoring is important, and consideration of overnight admission to an intensive care unit may be prudent for patients with severe right ventricular or biventricular dysfunction.

### CONDUCT OF THE CARDIAC CATHETERIZATION

In general, the conduct of the cardiac catheterization will depend on whether the child has a shunt, which will determine the information required to calculate flow and resistance. In addition, there is usually a requirement for hemodynamic evaluation under basal conditions (normal systemic arterial pH and CO<sub>2</sub>, normoxia) and assessment of the hemodynamic change after administration of a pulmonary vasodilator or temporary occlusion of a shunt.

The Fick principle is beguilingly simple and states that blood flow is proportional to the oxygen consumption divided by the extraction of oxygen across the same vascular bed. However, obtaining the information required to calculate flow is subject to multiple difficulties and errors and if incompletely understood leads to unreliable data, and therefore calculations of flow and resistance always should be interpreted as estimations within the context of the procedure.<sup>21</sup>

### MEASUREMENT OF OXYGEN CONSUMPTION

There have been many publications attesting to the unreliability of predicting oxygen consumption with tables and formulas.<sup>22-28</sup> However, there is no efficient, accurate, inexpensive, reliable, and user-friendly method to measure oxygen consumption ( $\dot{V}O_2$ ) in real time

and in real-life clinical settings, especially in intubated patients. The method closest to this ideal is the Innocor (Innovision, Odense, Denmark) breath-by-breath method, which correlates well with mass spectroscopy measurements in children undergoing cardiac catheterization but has yet to be validated in infants weighing less than 3.5 kg.<sup>29</sup>

Often,  $\dot{V}O_2$  is measured before intubation with a head box to collect expired gas in young children. The assumption that  $\dot{V}O_2$  does not change with interventions during the case is doubtful. In addition, the measurement of  $\dot{V}O_2$  in high inspired concentrations of oxygen is difficult, and it is impossible, at least in routine clinical practice, with an  $FiO_2$  (fraction of inspired oxygen) greater than 0.6–0.7. Again, the dubious assumption is made often that the  $\dot{V}O_2$  at baseline is similar to that obtained in an  $FiO_2$  of 1.0. In children without shunts in whom  $\dot{V}O_2$  is back-calculated from thermidilution, there may be a 30% change in the  $\dot{V}O_2$  in an  $FiO_2$  of 1.0, compared with that in an  $FiO_2$  of 0.21.<sup>30,31</sup>

The expression of the flows and resistances as a ratio is a mathematical ploy to minimize the effect of oxygen consumption. However, one should be cognizant that interventions such as hyperoxia may increase systemic vascular resistance and decrease the pulmonary vascular-to-systemic resistance ratio (PVR:SVR, or  $R_p:R_s$ ), without necessarily affecting PVRI (PVR index) or pulmonary resistance.<sup>32-34</sup>

### BLOOD SAMPLING TO MEASURE OXYGEN SATURATIONS

In general, blood sampling to measure the oxygen saturation for the calculation of flow should include samples proximal and distal to the shunt. Formulas for the calculation of a mixed venous sample from samples in the superior vena cava (SVC) and inferior vena cava in subjects with a shunt are available.<sup>21</sup> In general, to save time and blood, a sample in the SVC can be compared with one from the PA to detect the presence of a shunt and to calculate systemic and pulmonary blood flow. In practice, a step-up in oxygen saturation from the SVC to the PA of 3% or greater is likely to indicate the presence of a shunt. However, it should be remembered that a 6% saturation difference between the SVC and the PA or a 4% saturation difference between the right atrium or right ventricle and the PA may be a false-positive step up (i.e., a shunt is thought to be present when none in fact exists) in 5% of patients.<sup>35</sup> Most sources of error are related to sampling before complete mixing has occurred and to changes in physiologic state between sampling in different sites (Table 1).

Less common sources of error related to blood sampling may include failure to detect an anomalous pulmonary vein to the SVC or an innominate vein or differential saturations in the right and left PA in the presence of PDA or aortopulmonary collaterals, or failure to sample before and after the PDA in the aorta. Errors may be incurred by failure to recognize pulmonary vein desaturation or to assume that aortic desaturation is due to a right-to-left intracardiac shunt.

When there are multiple sources of pulmonary blood flow, for example, aortopulmonary collaterals after the Fontan operation, the collection of truly mixed PA saturation is difficult because the

Table 1. Causes of inaccuracy in flow and resistance calculations

Causes
Unstable baseline
Avoid acidosis
Avoid hypoxia
Changing hemodynamics
Minimize catheter manipulation
Minimize interval between samples
Assumptions: oxygen consumption, pulmonary vein saturation
Change in hemoglobin during case or using hemoglobin level from another day
More than single source of pulmonary blood flow
Unequal distribution of pulmonary blood flow
Sampling errors due to streaming, incorrect catheter position, small/diluted samples, delay in sample processing
Pressure measurements errors due to wedged catheter, damped pressure tracing, unstable zero reference level, severe pulmonary valve regurgitation
Magnification of error in hyperoxia by failing to include dissolved oxygen in calculation

Note: If assumptions are made, always consider best and worst scenario in calculations.

collaterals enter the pulmonary circulation distally. MRI may provide a better way of quantifying pulmonary and systemic blood flow in the evaluation of patients after the Fontan or cavopulmonary anastomoses.<sup>6</sup>

### HEMOGLOBIN

Changes in hemoglobin may affect pulmonary vascular resistance, not only through changes in viscosity but also because hemoglobin is integral to the Fick equation.<sup>36</sup> The shunt across a ventricular septal defect (VSD) is increased if the hemoglobin is low and decreased if, in the same patient, the hemoglobin is increased.<sup>37</sup>

In patients without cardiac or systemic-to-pulmonary shunts, the pulmonary and systemic blood flows are considered equivalent. Thermodilution catheters in the PA simplify the measurement of blood flow and calculation of resistance.<sup>38</sup> If thermodilution catheters are unavailable, then clearly only pulmonary and systemic artery saturations, hemoglobin, and  $\dot{V}_{O_2}$  are required to calculate pulmonary flow.

### ANATOMICAL CONSIDERATIONS IN THE CALCULATION OF FLOW AND RESISTANCE

In some situations, especially if blood flow and pressure are unequally distributed between the lungs, it may be difficult to estimate the total PVRI in a meaningful way. Examples of these situations include unequal distribution of pulmonary blood flow (e.g., hypoplasia of one lung) and unequal distribution of flow with different pressures in multiple lung segments (e.g., peripheral PA stenosis

or after PA unifocalization for pulmonary atresia with VSD and major aortopulmonary collaterals). In severe pulmonary valve regurgitation after the insertion of a right ventricle-to-PA conduit, it may not be possible to calculate the PVRI accurately because the diastolic pressure in the PA approximates the right ventricular end-diastolic pressure. Thus, the mean PA pressure will be decreased and lead to calculation of a PVRI lower than would be found if the pulmonary valve were competent. In these cases, careful evaluation of the individual case and integration of the information provided by angiography, MRI, or CT and lung perfusion scan are helpful. Furthermore, surgical decision making in these cases, especially if there is a shunt in the presence of unilateral lung hypoplasia, may be quite complex.<sup>39</sup>

### MEASUREMENT OF THE PA CAPACITANCE INDEX

The PA capacitance index (PACi) can be derived from routine information collected at cardiac catheterization and may offer insights into static right ventricle-to-PA coupling, which has been reported to be an important determinant of outcome in children with pulmonary vascular disease.<sup>40,41</sup> The PACi can be calculated with the following equation:

$$\frac{(\text{pulmonary blood flow indexed to body surface area}) \times (1,000/\text{heart rate})}{\text{systolic PA pressure} - \text{diastolic PA pressure}}$$

PACi values less than 0.7–0.9 mL/mmHg/m<sup>2</sup> have been suggested as predictors of poorer prognosis in children with PHVD.

PA distensibility<sup>42</sup> and studies of pulmonary flow and flow reserve may be included if an intravascular Doppler catheter is available or transthoracic echocardiography is available for use in the cardiac catheterization laboratory.<sup>43</sup> Pulmonary flow reserve of less than 1.4 is highly predictive of adverse events in children with idiopathic pulmonary arterial hypertension (IPAH).<sup>43</sup>

### ACUTE VASOREACTIVITY TESTING

In many institutions around the world, out of necessity, breathing 100% oxygen is used for pulmonary vasoreactivity testing.<sup>44</sup> However, there remains controversy about how well the response to breathing  $F_{iO_2}$  of 1.0 predicts operability.<sup>44,45</sup> The disadvantages of 100% oxygen are that it may decrease the accuracy of flows calculated by the Fick equation because the small arteriovenous  $O_2$  difference magnifies any saturation error, and calculated shunts will tend to be larger and resistances lower as a result. The  $\dot{V}_{O_2}$  cannot be accurately measured in 100% oxygen, and assumptions of  $\dot{V}_{O_2}$  are inaccurate, as discussed above. In addition, there is a suggestion that  $\dot{V}_{O_2}$  changes in 100% oxygen and decreases by 20%–30%, compared with that in room air. This change in  $\dot{V}_{O_2}$  is rarely taken into account, even if  $\dot{V}_{O_2}$  is measured under basal conditions. It is common practice to assume that  $\dot{V}_{O_2}$  remains constant despite changes in the  $F_{iO_2}$ .<sup>30,31</sup> Hyperoxia may increase the SVR and the shunt without a real change in PVR.<sup>32–34</sup>

The combination of oxygen and inhaled NO<sup>12,46,47</sup> may identify patients with significant pulmonary vasoreactivity who might not be recognized if  $O_2$  or NO were used separately. A combination of

40% O<sub>2</sub> with 20–40 ppm inhaled NO seems to work well, as  $\dot{V}O_2$  can be measured at this F<sub>IO<sub>2</sub></sub> and most hypoxic vasoconstriction will be reversed with less effect on the SVR in general.

Other agents that may be used for acute vasoreactivity testing include intravenous epoprostenol<sup>48,49</sup> and adenosine,<sup>50,51</sup> but they may result in systemic hypotension and have not been described well in children. Adenosine frequently causes side effects in comparison with inhaled NO.<sup>51</sup> Delivering pulmonary vasodilator drugs by inhalation or nebulization may promote pulmonary vascular selectivity and minimize adverse systemic reactions. Inhaled iloprost,<sup>52,53</sup> treprostinil,<sup>54</sup> nitroglycerin, and milrinone<sup>55</sup> have all been reported in children undergoing cardiac catheterization. Nevertheless, NO, if available was considered the current standard for acute vasoreactivity testing by the task force. Table 2 lists the drug doses recommended for acute vasoreactivity testing.

### Acute vasoreactivity testing in patients with systemic-to-pulmonary shunt lesions

In patients with pre- and posttricuspid systemic-to-pulmonary shunts, there is a general consensus that a decrease in PVRI below 4 Wood units (WU)·m<sup>2</sup> and/or in the ratio of pulmonary: systemic vascular resistance (PVRI:SVRI [SVR index]) below 0.3 indicates that shunt closure may be undertaken safely with a good long-term prognosis. If the PVRI is between 4 and 8 WU·m<sup>2</sup>, temporary balloon occlusion of the shunt, if possible, may provide additional useful information.<sup>56</sup> In some centers, a decrease in PVRI to less than 6–8 WU·m<sup>2</sup> may be used to undertake shunt closure, but it is emphasized that the individual center experience and resources for postoperative care, both short and long term, are important considerations.<sup>57–59</sup> The decision to close a shunt is made using all the available information and is not solely dependent on the hemodynamics obtained at cardiac catheterization.<sup>10,56,59</sup> Different criteria may be used, especially in older patients, to decide whether atrial septal defects ought to be closed, because a number of different factors affect atrial-level shunting and streaming that may be unrelated to pulmonary vascular resistance.<sup>60–62</sup>

### Acute vasoreactivity testing in patients without significant systemic-to-pulmonary shunts

In this subset of patients (usually with idiopathic PHVD, following repair of congenital heart disease, or with pulmonary hypertension due to left heart disease), cardiac output may be measured with thermodilution or the Fick principle. After a baseline evaluation of hemodynamics, acute vasoreactivity testing is suggested in patients with presumed idiopathic PHVD to identify those patients older than 1 year of age who may benefit from treatment with a calcium channel blocker.<sup>1</sup> The Sitbon<sup>63</sup> criterion for a positive response (decrease in mean pulmonary arterial pressure of >10 mmHg reaching <40 mmHg, with an increase or no change in cardiac output) is not always applicable to children, as some will have mean pulmonary arterial pressure lower than 40 mmHg even in the presence of severe PHVD. Barst<sup>64,65</sup> proposed a specific definition of a positive test for children: decrease in mean PA pressure of >20%, an increase or no change in cardiac index, and a decrease or no change in PVRI:SVRI. This definition of acute vasoreactivity correctly identified children in the REVEAL registry who reacted well to long-term calcium channel blocker therapy, and none of these 22 children treated with calcium channel blocker therapy, as either mono or combination therapy, died or underwent transplantation within 5 years of follow-up.<sup>65</sup> However, the Barst criteria were not associated with prolonged survival or continued response to calcium channel blockers in the pediatric IPAH UK registry. The authors of the pediatric IPAH UK registry suggested that, provided that the PVRI decreased to 4.5 WU·m<sup>2</sup> or less, the long-term response to calcium channel blockers was good. They noted that the condition of 2 of 5 children with a PVRI > 5 WU·m<sup>2</sup> deteriorated and suggested that stricter acute vasoreactivity criteria be used to predict long-term response with near normalization of PA pressures and resistance.<sup>66</sup> In other published registries or cohorts, the reported proportion of children with IPAH who were acute responders has been quite variable: 17%–20% in the Van Loon et al.<sup>67</sup> series, 11% in the French registry,<sup>68</sup> 6% in the Spanish registry,<sup>69</sup> and 9% in the UK registry.<sup>66</sup> Differences in the patient

Table 2. Agents used for acute pulmonary vasoreactivity testing in children

Drug	Doses reported
Inhaled nitric oxide	20–80 ppm
Inhaled iloprost	0.5 µg/kg for patients <15 kg; 5 µg for patients > 15 kg
Inhaled prostacyclin	5–50 ng/kg/min
Inhaled treprostinil	1.53 µg/kg (range: 0.71–2.89)
Inhaled milrinone <sup>a</sup>	50 µg/kg
Inhaled nitroglycerin <sup>a</sup>	50 µg/kg
Intravenous prostacyclin	2–10 ng/kg/min dose titration: 2 ng/kg/min every 10–15 min
Intravenous adenosine <sup>b</sup>	50–250 µg/kg/min dose titration: 50 µg/kg/min every 2 min

<sup>a</sup> Both inhaled nitroglycerine and milrinone are prepared by mixing the drug with normal saline to make a volume of 3 mL and nebulized over 10 minutes with a jet nebulizer using 8 L/min of 50% air-oxygen mixture.

<sup>b</sup> Adenosine use is controversial, and there is a lack of information reporting its use in children.

population included in these series are probably responsible for the variations in the proportion of responders. Thus, for children with idiopathic PHVD, the task force recommends that strict criteria with near-normalization of PA pressure, as suggested by Sitbon,<sup>63</sup> and PVRI < 4.5 WU·m<sup>2</sup>, as suggested by Moledina,<sup>66</sup> be used to define an acute responder. It is prudent to exclude, as far as possible, the diagnosis of pulmonary veno-occlusive disease before undertaking acute pulmonary vasoreactivity trials, because these patients have a variable response to pulmonary vasodilation but may respond with severe, sometimes fatal, pulmonary edema.

The evaluation of patients with systolic dysfunction of the left ventricle may include an infusion of dobutamine, milrinone, or sodium nitroprusside to decrease the LV end-diastolic pressure and to increase the cardiac output; this may result in a decrease in PVRI below 4 WU·m<sup>2</sup>; if PVRI remains higher than 4–6 WU·m<sup>2</sup> and the transpulmonary gradient greater than 15 mmHg, vasoreactivity testing with inhaled NO may be used, but with caution, because of the risk of inducing pulmonary edema. However, in our experience, the use of inhaled NO in patients with cardiomyopathy is generally well tolerated even if there is an increase in left ventricular end-diastolic or PA wedge pressure. There is considerable interest in using the diastolic pressure gradient between the PA pressure and the LV end-diastolic pressure or the wedge pressure to assess the variable contribution of pulmonary arterial vascular changes in left heart dysfunction.<sup>70,71</sup>

In patients with postoperative PHVD or Eisenmenger syndrome, the role of vasoreactivity testing is less clear, because very few patients have been treated with calcium channel blockers.<sup>72</sup> However, response to inhaled NO suggests a better prognosis and response to therapy in established Eisenmenger syndrome.<sup>73–75</sup> If patients with repaired congenital heart disease undergo cardiac catheterization to evaluate pulmonary hypertension, then it is important to assess for residual shunts, diastolic dysfunction, and pericardial disease, as they may contribute to pulmonary hypertension.

## ANGIOGRAPHY

Contrast angiography is not without risk in children with PHVD. We suggest that all data be reviewed before angiography. Evaluation by echocardiography (transthoracic and transesophageal), contrast high-resolution CT, and MRI has significantly reduced the need for routine angiography. Angiography should be performed judiciously and is necessary only to answer specific questions or if there is doubt about interpretation of other imaging modalities.

Although not performed routinely, balloon occlusion pulmonary wedge angiography may provide information about the severity of pulmonary vascular disease<sup>76,77</sup> and provides excellent visualization of the pulmonary veins. It also allows for the identification of segmental and subsegmental pulmonary arterial branch stenoses and may be useful in detecting pulmonary arteriovenous malformations. It is usually performed in both lungs, preferably in the posterobasal segment artery of the right or left lower lobe (1 rib space below the takeoff of the right PA or 2 rib spaces below the takeoff of the left PA). Once the balloon is inflated, contrast is injected at 0.3 mL/kg (minimum 2 mL) at a flow rate of 5 mL/s. We use layered contrast with saline to wash the contrast through the vascular bed.

## CONCLUSIONS

Cardiac catheterization plays an important role in the diagnosis and evaluation of PHVD in children. However, the need for cardiac catheterization should always be considered carefully, as the risks involved are higher than those in adults.

**Source of Support:** Nil.

**Conflict of Interest:** None declared.

## REFERENCES

- Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, Haworth SG, et al. Pediatric pulmonary hypertension. *J Am Coll Cardiol* 2013;62(25 suppl.):D117–D126.
- Adatia I, Haworth SG, Wegner M, Barst RJ, Ivy D, Stenmark KR, Karkowsky A, Rosenzweig E, Aguilar C. Clinical trials in neonates and children: report of the pulmonary hypertension academic research consortium pediatric advisory committee. *Pulm Circ* 2013;3(1):252–266.
- McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol* 2009;53(17):1573–1619.
- Lammers AE, Adatia I, del Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. Functional classification of pulmonary hypertension in children: report from the PVRI Pediatric Taskforce, Panama 2011. *Pulm Circ* 2011;1(2):280–285.
- del Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, Haworth SG, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. *Pulm Circ* 2011;1(2):286–298.
- Grosse-Wortmann L, Al-Otay A, Yoo SJ. Aortopulmonary collaterals after bidirectional cavopulmonary connection or Fontan completion: quantification with MRI. *Circ Cardiovasc Imaging* 2009;2(3):219–225.
- Moledina S, Pandya B, Bartsota M, Mortensen KH, McMillan M, Quyam S, Taylor AM, Haworth SG, Schulze-Neick I, Muthurangu V. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. *Circ Cardiovasc Imaging* 2013;6(3):407–414.
- Pandya B, Quail MA, Steeden JA, McKee A, Odille F, Taylor AM, Schulze-Neick I, Derrick G, Moledina S, Muthurangu V. Real-time magnetic resonance assessment of septal curvature accurately tracks acute hemodynamic changes in pediatric pulmonary hypertension. *Circ Cardiovasc Imaging* 2014;7(4):706–713.
- Beghetti M, Berger RM, Schulze-Neick I, Day RW, Pulido T, Feinstein J, Barst RJ, Humpl T. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. *Eur Respir J* 2013;42(3):689–700.
- Lopes AA, Barst RJ, Haworth SG, Rabinovitch M, Al Dabbagh M, del Cerro MJ, Ivy D, et al. Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). *Pulm Circ* 2014;4(2):330–341.
- Bobhate P, Guo L, Jain S, Haugen R, Coe JY, Cave D, Rutledge J, Adatia I. Cardiac catheterization in children with pulmonary hypertensive vascular disease. *Pediatr Cardiol* 2015;36(4):873–879.
- Hill KD, Lim DS, Everett AD, Ivy DD, Moore JD. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. *Catheter Cardiovasc Intervention* 2010;76(6):865–873.

13. Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. *Br J Anaesth* 2007;98(5):657–661.
14. Carosino MJ, Friesen RH, Doran A, Ivy DD. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. *Anesth Analg* 2007;104(3):521–527.
15. Williams GD, Maan H, Ramamoorthy C, Kamra K, Bratton SL, Bair E, Kuan CC, Hammer GB, Feinstein JA. Perioperative complications in children with pulmonary hypertension undergoing general anesthesia with ketamine. *Paediatr Anaesth* 2010;20(1):28–37.
16. Williams GD, Philip BM, Chu LF, Boltz MG, Kamra K, Terwey H, Hammer GB, Perry SB, Feinstein JA, Ramamoorthy C. Ketamine does not increase pulmonary vascular resistance in children with pulmonary hypertension undergoing sevoflurane anesthesia and spontaneous ventilation. *Anesth Analg* 2007;105(6):1578–1584.
17. Zuckerman WA, Turner ME, Kerstein J, Torres A, Vincent JA, Krishnan U, Kerstein D, Rosenzweig EB. Safety of cardiac catheterization at a center specializing in the care of patients with pulmonary arterial hypertension. *Pulm Circ* 2013;3(4):831–839.
18. O'Byrne ML, Glatz AC, Hanna BD, Shinohara RT, Gillespie MJ, Dori Y, Rome JJ, Kawut SM. Predictors of catastrophic adverse outcomes in children with pulmonary hypertension undergoing cardiac catheterization: a multi-institutional analysis from the pediatric health information systems database. *J Am Coll Cardiol* 2015;66(11):1261–1269.
19. Shukla AC, Almodovar MC. Anesthesia considerations for children with pulmonary hypertension. *Pediatr Crit Care Med* 2010;11(suppl.):S70–S73.
20. Vlahakes GJ, Turley K, Hoffman JIE. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. *Circulation* 1981;63(1):87–95.
21. Wilkinson JL. Haemodynamic calculations in the catheter laboratory. *Heart* 2001;85(1):113–120.
22. Lundell BP, Casas ML, Wallgren CG. Oxygen consumption in infants and children during heart catheterization. *Pediatr Cardiol* 1996;17(4):207–213.
23. Laitinen PO, Räsänen J. Measured versus predicted oxygen consumption in children with congenital heart disease. *Heart* 1998;80(6):601–605.
24. Wolf A, Pollman MJ, Trindade PT, Fowler MB, Alderman EL. Use of assumed versus measured oxygen consumption for the determination of cardiac output using the Fick principle. *Catheter Cardiovasc Diagn* 1998;43(4):372–380.
25. Li J, Bush A, Schulze-Neick I, Penny DJ, Redington AN, Shekerdemia LS. Measured versus estimated oxygen consumption in ventilated patients with congenital heart disease: the validity of predictive equations. *Crit Care Med* 2003;31(4):1235–1240.
26. Fakler U, Pauli C, Hennig M, Sebening W, Hess J. Assumed oxygen consumption frequently results in large errors in the determination of cardiac output. *J Thorac Cardiovasc Surg* 2005;130(2):272–276.
27. Rutledge J, Bush A, Shekerdemia L, Schulze-Neick I, Penny D, Cai S, Li J. Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—a revisit. *Am Heart J* 2010;160(1):109–114.
28. Schmitz A, Kretschmar O, Knirsch W, Woitzek K, Balmer C, Tomaske M, Bauersfeld U, Weiss M. Comparison of calculated with measured oxygen consumption in children undergoing cardiac catheterization. *Pediatr Cardiol* 2008;29(6):1054–1058.
29. Guo L, Cui Y, Pharis S, Walsh M, Atallah J, Tan MW, Rutledge J, Coe JY, Adatia I. Measurement of oxygen consumption in children undergoing cardiac catheterization: comparison between mass spectrometry and the breath-by-breath method. *Pediatr Cardiol* 2014;35(5):798–802.
30. Beekman RH, Rocchini AP, Rosenthal A. Cardiovascular effects of breathing 95 percent oxygen in children with congenital heart disease. *Am J Cardiol* 1983;52(1):106–111.
31. Guo L, Bobhate P, Jain S, Coe JY, Rutledge J, Adatia I. Hyperoxia reduces oxygen consumption in children with pulmonary hypertension. Paper presented at the American Heart Association Scientific Sessions and ReSuscitation Science Symposium; November 15–16, 2014; Chicago. *Circulation* 130(suppl. 2):A19033.
32. Marshall HW, Swan HJC, Burchell HB, Wood EH. Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. *Circulation* 1961;23(2):241–252.
33. Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. *J Am Coll Cardiol* 2010;56(13):1013–1016.
34. Waring WS, Thomson AJ, Adwani SH, Rosseel AJ, Potter JF, Webb DJ, Maxwell SR. Cardiovascular effects of acute oxygen administration in healthy adults. *J Cardiovasc Pharmacol* 2003;42(2):245–250.
35. Freed MD, Miettinen OS, Nadas AS. Oximetric detection of intracardiac left-to-right shunts. *Br Heart J* 1979;42(6):690–694.
36. Hoffman JI. Pulmonary vascular resistance and viscosity: the forgotten factor. *Pediatr Cardiol* 2011;32(5):557–561.
37. Lister G, Hellenbrand WE, Kleinman CS, Talner NS. Physiologic effects of increasing hemoglobin concentration in left-to-right shunting in infants with ventricular septal defects. *N Engl J Med* 1982;306(9):502–506.
38. Freed M, Keane J. Cardiac output measurement by thermodilution in infants and children. *J Pediatr* 1978;92(1):39–42.
39. Mair DD, Ritter DG, Davis GD, Wallace RB, Danielson GK, McGoon DC. Selection of patients with truncus arteriosus for surgical correction. *Circulation* 1974;49(1):144–151.
40. Douwes JM, Roofthoof MT, Bartelds B, Talsma MD, Hillege HL, Berger RM. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. *Int J Cardiol* 2013;168(2):1370–1377.
41. Sajan I, Manlhiot C, Reyes J, McCrindle BW, Humpl T, Friedberg MK. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. *Am Heart J* 2011;162(3):562–568.
42. Berger RM, Cromme-Dijkhuis AH, Hop WC, Kruit MN, Hess J. Pulmonary arterial wall distensibility assessed by intravascular ultrasound in children with congenital heart disease: an indicator for pulmonary vascular disease? *Chest* 2002;122(2):549–557.
43. Apitz C, Zimmermann R, Kreuder J, Jux C, Latus H, Pons-Kühnemann J, Kock I, et al. Assessment of pulmonary endothelial function during invasive testing in children and adolescents with idiopathic pulmonary arterial hypertension. *J Am Coll Cardiol* 2012;60(2):157–164.
44. Gan HL, Zhang JQ, Zhou QW, Feng L, Chen F, Yang Y. Patients with congenital systemic-to-pulmonary shunts and increased pulmonary vascular resistance: what predicts postoperative survival? *PloS ONE* 2014;9:e83976. doi:10.1371/journal.pone.0083976.
45. Lock JE, Einzig S, Bass JL, Moller JH. The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. *Pediatr Cardiol* 1982;3(1):41–46.
46. Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. *J Am Coll Cardiol* 1999;33(3):813–819.
47. Barst RJ, Agnoletti G, Fraise A, Baldassarre J, Wessel DL. Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension. *Pediatr Cardiol* 2010;31(5):598–606.
48. Maron BA, Bhatt DL, Nykiel M, Kinlay S, Waxman AB. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension. *Crit Pathw Cardiol* 2012;11(1):40–42.
49. Bush A, Busst C, Booth K, Knight WB, Shinebourne EA. Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease? *Circulation* 1986;74(1):135–144.
50. Zuo XR, Zhang R, Jiang X, Li XL, Zong F, Xie WP, Wang H, Jing ZC. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers. *Am J Cardiol* 2012;109(12):1801–1806.
51. Oliveira EC, Ribeiro AL, Amaral CF. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. *Respir Med* 2010;104(4):606–611.
52. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital



- heart disease: vasodilator capacity and cellular mechanisms. *Circulation* 2001;103(4):544–548.
53. Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. *Catheter Cardiovasc Intervention* 2009;73(1):98–104.
  54. Takatsuki S, Parker DK, Doran AK, Friesen RH, Ivy DD. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. *Pediatr Cardiol* 2013;34(4):1006–1012.
  55. Singh R, Choudhury M, Saxena A, Kapoor PM, Juneja R, Kiran U. Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension. *J Cardiothorac Vasc Anesth* 2010;24(5):797–801.
  56. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. *Catheter Cardiovasc Intervention* 2008;71(5):665–670.
  57. Neutze JM, Ishikawa T, Clarkson PM, Calder AL, Barratt-Boyes BG, Kerr AR. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. *Am J Cardiol* 1989;63(5):327–331.
  58. Bush A, Busst CM, Haworth SG, Hislop AA, Knight WB, Corrin B, Shinebourne EA. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. *Br Heart J* 1988;59(4):480–485.
  59. Kannan BR, Sivasankaran S, Tharakan JA, Titus T, Ajith Kumar VK, Francis B, Krishnamoorthy KM, Harikrishnan S, Padmakumar R, Nair K. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. *Indian Heart J* 2003;55(2):161–166.
  60. Steele PM, Fuster V, Cohen M, Ritter DG, McGoan DC. Isolated atrial septal defect with pulmonary vascular obstructive disease—long-term follow-up and prediction of outcome after surgical correction. *Circulation* 1987;76(5):1037–1042.
  61. Gabriels C, De Meester P, Pasquet A, De Backer J, Paelinck BP, Morissens M, Van De Bruaene A, Delcroix M, Budts W. A different view on predictors of pulmonary hypertension in secundum atrial septal defect. *Int J Cardiol* 2014;176(3):833–840.
  62. Goetschmann S, DiBernardo S, Steinmann H, Pavlovic M, Sekarski N, Pfammatter JP. Frequency of severe pulmonary hypertension complicating “isolated” atrial septal defect in infancy. *Am J Cardiol* 2008;102(3):340–342.
  63. Sitbon O, Humbert M, Jaïs X, Iqbal V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation* 2005;111(23):3105–3111.
  64. Barst RJ. Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. *Chest* 1986;89(4):497–503.
  65. Barst RJ, McGoan DC, Elliot CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. *Circulation* 2012;125(1):113–122.
  66. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. *Heart* 2010;96(17):1401–1406.
  67. van Loon RL, Roofthoof MT, Delhaas T, van Osch-Gevers M, ten Harkel AD, Strengers JL, Backx A, Hillege HL, Berger RM. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. *Am J Cardiol* 2010;106(1):117–124.
  68. Fraisse A, Jaïs X, Schleich JM, di Filippo S, Maragnès P, Beghetti M, Gressin V, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. *Arch Cardiovasc Dis* 2010;103(2):66–74.
  69. del Cerro Marín MJ, Sabate Rotés A, Rodríguez Ogando A, Mendoza Soto A, Quero Jiménez M, Gavilán Camacho JL, Raposo Sonnenfeld I, Moya Bonora A, Albert Brotons DC, Moreno Galdó A. Assessing pulmonary hypertensive vascular disease in childhood: data from the Spanish registry. *Am J Respir Crit Care Med* 2014;190(12):1421–1429.
  70. Naeije R, Vachiéry JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. *Eur Respir J* 2013;41(1):217–223.
  71. Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, Maurer G, Lang IM. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. *Chest* 2013;143(3):758–766.
  72. Wimmer M, Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger’s mechanism in children. *Cardiovasc Drugs Ther* 1992;6:183–186.
  73. Budts W, Van Pelt N, Gillyns H, Gewillig M, Van de Werf F, Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. *Heart* 2001;86(5):553–558.
  74. Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. *Eur Heart J* 2004;25:1651–1656.
  75. D’Alto M, Romeo E, Argiento P, Santoro G, Sarubbi B, Gaio G, Mélot C, Russo MG, Naeije R, Calabrò R. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. *Heart* 2010;96(18):1475–1479.
  76. Rabinovitch M, Keane J, Fellows K, Castañeda A, Reid L. Quantitative analysis of the pulmonary artery wedge angiogram in congenital heart defects: correlation with hemodynamic data and morphometric findings in lung biopsy tissue. *Circulation* 1981;63(1):152–164.
  77. Rabinovitch M, Haworth SG. Balloon occlusion pulmonary wedge angiography and lung biopsy assessment in the child with a congenital cardiac defect. *Cardiol Young* 2009;19(suppl. S1):13–15.